Teratology: From science to birth defects prevention

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 1, 2009, Pages 82-92

  Rasmussen, Sonja A ^a,c   Erickson, J David ^a   Reef, Susan E ^b   Ross, Danielle S ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Congenital rubella syndrome; Cytomegalovirus; Fetal alcohol syndrome; Folic acid; Neural tube defects; Prevention; Vaccine

Indexed keywords

ALCOHOL; FOLIC ACID; GANCICLOVIR; HYPERIMMUNE GLOBULIN; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE;

ANENCEPHALUS; BIRTH DEFECT; CONGENITAL RUBELLA SYNDROME; CYTOMEGALOVIRUS INFECTION; FETAL ALCOHOL SYNDROME; HUMAN; NEURAL TUBE DEFECT; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RUBELLA; RUBELLA VIRUS; SPINA BIFIDA; TERATOGENICITY; TERATOLOGY; ADULT; CONGENITAL DISORDER; FEMALE; MEDICAL RESEARCH; METHODOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; VIROLOGY;

CYTOMEGALOVIRUS; RUBELLA; RUBELLA VIRUS;

ADULT; BIOMEDICAL RESEARCH; CONGENITAL ABNORMALITIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FETAL ALCOHOL SYNDROME; HUMANS; INFANT, NEWBORN; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RUBELLA SYNDROME, CONGENITAL; TERATOLOGY;

EID: 59849108858     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20506     Document Type: Review

References (164)

1. Abel EL. 1988. Fetal alcohol syndrome in families. 10:1-2.
2. Adler SP. 2008. Human CMV vaccine trials: what if CMV caused a rash? J Clin Virol 41:231-236.
3. Adler SP, Finney JW, Manganello AM, et al. 2004. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 145:485-491.
4. Adler SP, Nigro G, Pereira L. 2007. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin Perinatol 31:10-18.
5. Barbi M, Binda S, Caroppo S. 2006a. Diagnosis of congenital CMV infection via dried blood spots. Rev Med Virol 16:385-392.
6. Barbi M, Binda S, Caroppo S, et al. 2006b. Neonatal screening for congenital cytomegalovirus infection and hearing loss. J Clin Virol 35:206-209.
7. Barbi M, Binda S, Primache V, et al. 1996. Diagnosis of congenital cytomegalovirus infection by detection of viral DNA in dried blood spots. Clin Diagn Virol 6:27-32.
8. Bart KJ, Orenstein WA, Hinman AR. 1986. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles. Dev Biol Stand 65:45-52.
9. Becerra JE, Khoury MJ, Cordero JF, et al. 1990. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 85:1-9.
10. Becker HC, Diaz-Granados JL, Randall CL. 1996. Teratogenic actions of ethanol in the mouse: a minireview. Pharmacol Biochem Behav 55:501-513.
11. Berry RJ, Li Z, Erickson JD, et al. 1999. Prevention of neural-tube defects with folic acid in China. China-U.S. collaborative project for neural tube defect prevention. N Engl J Med 341:1485-1490.
12. Bertrand J, Floyd LL, Weber MK. 2005. Guidelines for identifying and referring persons with fetal alcohol syndrome. MMWR Recomm Rep 54:1-14.
13. Best JM, Castillo-Solorzano C, Spika JS, et al. 2005. Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee on Research Related To Measles and Rubella Vaccines and Vaccination, J Infect Dis 192:1890-1897.
14. Blom HJ, Shaw GM, den Heijer M, et al. 2006. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 7:724-731.
15. Boehm SL, 2nd, Lundahl KR, Caldwell J, et al. 1997. Ethanol teratogenesis in the C57BL/6J, DBA/2J, and A/J inbred mouse strains Alcohol 14:389-395.
16. Bower C, Stanley FJ. 1989. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 150:613-619.
17. Boyles AL, Billups AV, Deak KL, et al. 2006. Neural tube defects and folate pathway genes: family-based association tests of gene-gene and gene-environment interactions. Environ Health Perspect 114:1547-1552.
18. Brent RL, Oakley GP, Jr. 2005. The Food and Drug Administration must require the addition of more folic acid in "enriched" flour and other grains. Pediatrics 116:753-755.
19. Brent RL, Oakley GP, Jr. 2006. Triumph and/or tragedy: the present Food and Drug Administration program of enriching grains with folic acid. Pediatrics 117:930-932.
20. Burgess MA. 1991. Gregg's rubella legacy 1941-1991. Med J Aust 155:355-357.
21. Cabrera RM, Hill DS, Etheredge AJ, et al. 2004. Investigations into the etiology of neural tube defects. Birth Defects Res C Embryo Today 72:330-344.
22. Calhoun F, Warren K. 2007. Fetal alcohol syndrome: historical perspectives. Neurosci Biobehav Rev 31:168-171.
23. Callaghan WM, MacDorman MF, Rasmussen SA, et al. 2006. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 118:1566-1573.
24. Cannon MJ, Davis KF. 2005. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 5:70.
25. Carey JC. 2008. Where observation is concerned, chance favors only the prepared mind. Obstet Gynecol 111:479-480.
26. Castillo-Solorzano C, Andrus JK. 2004. Rubella elimination and improving health care for women. Emerg Infect Dis 10:2017-2021.
27. Centers for Disease Control and Prevention. 1983. Valproate: a new cause of birth defects - report from Italy and follow-up from France. MMWR Morb Mortal Wkly Rep 32:438-439.
28. Centers for Disease Control and Prevention. 1989. Measles prevention. MMWR Morb Mortal Wkly Rep 38 Suppl 9:1-18.
29. Centers for Disease Control and Prevention. 1991. Use of folic acid for prevention of spina bifida and other neural tube defects - 1983-1991. MMWR Morb Mortal Wkly Rep 40:513-516.
30. Centers for Disease Control and Prevention. 1992. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 41:1-7.
31. Centers for Disease Control and Prevention. 1994a. Reported vaccine-preventable diseases - United States, 1993, and the childhood immunization initiative. MMWR Morb Mortal Wkly Rep 43:57-60.
32. Centers for Disease Control and Prevention. 1994b. Addressing emerging infectious disease threats: a prevention strategy for the United States. Executive summary. MMWR Recomm Rep 43:1-18.
33. Centers for Disease Control and Prevention. 1995. Birth certificates as a source for fetal alcohol syndrome case ascertainment - Georgia, 1989-1992. MMWR Morb Mortal Wkly Rep 44:251-253.
34. Centers for Disease Control and Prevention. 2004. Alcohol consumption among women who are pregnant or who might become pregnant - United States, 2002. MMWR Morb Mortal Wkly Rep 53:1178-1181.
35. Centers for Disease Control and Prevention. 2005. Elimination of rubella and congenital rubella syndrome - United States, 1969-2004. MMWR Morb Mortal Wkly Rep 54:279-282.
36. Centers for Disease Control and Prevention. 2008a. Update on overall prevalence of major birth defects - Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 57:1-5.
37. Centers for Disease Control and Prevention. 2008b. Use of supplements containing folic acid among women of childbearing age - United States, 2007. MMWR Morb Mortal Wkly Rep 57:5-8.
38. Centers for Disease Control and Prevention. 2008c. Knowledge and practices of obstetricians and gynecologists regarding cytomegalovirus infection during pregnancy - United States, 2007. MMWR Morb Mortal Wkly Rep 57:65-68.
39. Chang G, McNamara TK, Orav EJ, et al. 2005. Brief intervention for prenatal alcohol use: a randomized trial. Obstet Gynecol 105:991-998.
40. Chernoff GF. 1980. The fetal alcohol syndrome in mice: maternal variables. Teratology 22:71-75.
41. Christoffel KK, Salafsky I. 1975. Fetal alcohol syndrome in dizygotic twins. J Pediatr 87:963-967.
42. Clarren SK, Smith DW. 1978. The fetal alcohol syndrome. Lamp 35:4-7.
43. Correa-Villasenor A, Cragan J, Kucik J, et al. 2003. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol 67:617-624.
44. Craig JM, Macauley JC, Weller TH, et al. 1957. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 94:4-12.
45. Czeizel AE, Dudas I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832-1835.
46. Dayan GH, Castillo-Solorzano C, Nava M, et al. 2006. Efforts at rubella elimination in the United States: the impact of hemispheric rubella control. Clin Infect Dis 43:S158-163.
47. De Santis M, Cavaliere AF, Straface G, et al. 2006. Rubella infection in pregnancy. Reprod Toxicol 21:390-398.
48. De Wals P, Tairou F, Van Allen MI, et al. 2007. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 357:135-142.
49. Dollard SC, Grosse SD, Ross DS. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17:355-363.
50. Druschel CM, Fox DJ. 2007. Issues in estimating the prevalence of fetal alcohol syndrome: examination of 2 counties in New York State. Pediatrics 119:e384-390.
51. Edwards EM, Werler MM. 2006. Alcohol consumption and time to recognition of pregnancy. Matern Child Health J 10:467-472.
52. Egeland GM, Perham-Hester KA, Gessner BD, et al. 1977 through 1992: an administrative prevalence derived from multiple data sources. Am J Public Health 1998. Fetal alcohol syndrome in Alaska, 88:781-786.
53. Eichholzer M, Tonz O, Zimmermann R. 2006. Folic acid: a public-health challenge. Lancet 367:1352-1361.
54. Elwood JM, Little J, Elwood JH. 1992. Epidemiology and control of neural tube defects. Oxford, England: Oxford University Press.
55. Ethen MK, Ramadhani TA, Scheuerle AE, et al. 2008. Alcohol consumption by women before and during pregnancy. Matern Child Health J [Epub ahead of print].
56. FASD Regional Training Centers Consortium. 2007. Educating health professionals about fetal alcohol spectrum disorders. Am J Health Ed 38:364-373.
57. Ferrier PE, Nicod I, Ferrier S. 1973. Letter: Fetal alcohol syndrome. Lancet 2:1496.
58. Finer LB, Henshaw SK. 2006. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38:90-96.
59. Floyd RL, Decoufle P, Hungerford DW. 1999. Alcohol use prior to pregnancy recognition. Am J Prev Med 17:101-107.
60. Floyd RL, Sobell M, Velasquez MM, et al. 2007. Preventing alcohol-exposed pregnancies: a randomized controlled trial. Am J Prev Med 32:1-10.
61. Food and Drug Administration. 1996. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Register 61:8781-8788.
62. Fowler KB, Stagno S, Pass RF, et al. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663-667.
63. Gilliam DM, Irtenkauf KT. 1990. Maternal genetic effects on ethanol teratogenesis and dominance of relative embryonic resistance to malformations. Alcohol Clin Exp Res 14:539-545.
64. Gilliam DM, Mantle MA, Barkhausen DA, et al. 1997. Effects of acute prenatal ethanol administration in a reciprocal cross of C57BL/6J and short-sleep mice: maternal effects and nonmaternal factors. Alcohol Clin Exp Res 21:28-34.
65. Green-Raleigh K, Carter H, Mulinare J, et al. 2006. Trends in folic acid awareness and behavior in the United States: the Gallup Organization for the March of Dimes Foundation surveys, 1995-2005. Matern Child Health J 10:S177-182.
66. Green LW, Orleans CT, Ottoson JM, et al. 2006. Inferring strategies for disseminating physical activity policies, programs, and practices from the successes of tobacco control. Am J Prev Med 31:S66-S81.
67. Green RF, Stoler JM. 2007. Alcohol dehydrogenase 1B genotype and fetal alcohol syndrome: a HuGE minireview. Am J Obstet Gynecol 197:12-25.
68. Greenberg M, Pellitteri O, Barton J. 1957. Frequency of defects in infants whose mothers had rubella during pregnancy. J Am Med Assoc 165:675-678.
69. Gregg NM. 1941. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 3:35-46.
70. Gregg NM. 1944. Further observations on congenital defects in infants following maternal rubella. Trans Ophthalmol Soc Aust 4:119-131.
71. Griffiths PD. 2006. Happy anniversary for human cytomegalovirus. Rev Med Virol 16:349-352.
72. Grosse SD, Waitzman NJ, Romano PS, et al. 2005. Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. Am J Public Health 95:1917-1922.
73. Hanshaw JB. 1966. Congenital and acquired cytomegalovirus infection. Pediatr Clin North Am 13:279-293.
74. Hanson JW, Jones KL, Smith DW. 1976. Fetal alcohol syndrome. Experience with 41 patients. JAMA 235:1458-1460.
75. Hassan J, Connell J. 2007. Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on. Clin Exp Immunol 149:205-210.
76. Hibbard ED, Smithells RW. 1965. Folic acid metabolism and human embyropathy. Lancet 1:1254.
77. Ho M. 2008. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 197:65-73.
78. Honein MA, Paulozzi LJ, Mathews TJ, et al. 2001. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981-2986.
79. Hoyme HE, May PA, Kalberg WO, et al. 2005. A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine criteria. Pediatrics 115:39-47.
80. Hymbaugh K, Miller LA, Druschel CM, et al. 2002. A multiple source methodology for the surveillance of fetal alcohol syndrome - The Fetal Alcohol Syndrome Surveillance Network (FASSNet). Teratology 66:S41-49.
81. Institute of Medicine Committee to Study Fetal Alcohol Syndrome. 1996. Fetal Alcohol Syndrome: Diagnosis, epidemiology, prevention, and treatment. Washington, DC: National Academies Press.
82. Institute of Medicine Committee to Study Priorities for Vaccine Development. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, D.C.: National Academies Press.
83. Jeon J, Victor M, Adler SP, et al. 2006. Knowledge and awareness of congenital cytomegalovirus among women. Infect Dis Obstet Gynecol 2006:80383.
84. Johnston RB, Jr. 2008. Will increasing folic acid in fortified grain products further reduce neural tube defects without causing harm?: consideration of the evidence. Pediatr Res 63:2-8.
85. Jones KL. 2003. From recognition to responsibility: Josef Warkany, David Smith, and the fetal alcohol syndrome in the 21st century Birth Defects Res A Clin Mol Teratol 67:13-20.
86. Jones KL, Robinson LK, Bakhireva LN, et al. 2006. Accuracy of the diagnosis of physical features of fetal alcohol syndrome by pediatricians after specialized training. Pediatrics 118:e1734-1738.
87. Jones KL, Smith DW. 1973. Recognition of the fetal alcohol syndrome in early infancy. Lancet 2:999-1001.
88. Jones KL, Smith DW. 1975. The fetal alcohol syndrome. Teratology 12:1-10.
89. Jones KL, Smith DW, Ulleland CN, Streissguth P. 1973. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet 1:1267-1271.
90. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253-276.
91. Khanna R, Diamond DJ. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26-33.
92. Kimberlin DW, Lin CY, Sanchez PJ, et al. 2003. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 143:16-25.
93. Kodituwakku PW. 2007. Defining the behavioral phenotype in children with fetal alcohol spectrum disorders: a review. Neurosci Biobehav Rev 31:192-201.
94. Lammer EJ, Chen DT, Hoar RM, et al. 1985. Retinoic acid embryopathy. N Engl J Med 313:837-841.
95. Laurence KM, James N, Miller MH, et al. 1981. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 282:1509-1511.
96. Lemoine P, Harousseau H, Borteyru JP, et al. 2003. Children of alcoholic parents-observed anomalies: discussion of 127 cases. Ther Drug Monit 25:132-136.
97. Little BB, Snell LM, Rosenfeld CR, et al. 1990. Failure to recognize fetal alcohol syndrome in newborn infants. Am J Dis Child 144:1142-1146.
98. Little J, Cardy A, Munger RG. 2004. Tobacco smoking and oral clefts: a meta-analysis. Bull World Health Organ 82:213-218.
99. Lopez-Camelo JS, Orioli IM, da Graca Dutra M, et al. 2005. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A 135:120-125.
100. Lundstrom R. 1952. Rubella during pregnancy, its effects upon perinatal mortality, the incidence of congenital abnormalities and immaturity. Acta Paediatr 41:583-594.
101. Manwell LB, Fleming MF, Mundt MP, et al. 2000. Treatment of problem alcohol use in women of childbearing age: results of a brief intervention trial. Alcohol Clin Exp Res 24:1517-1524.
102. Marin M, Guris D, Chaves SS, et al. 2007. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1-40.
103. Mattson SN, Riley EP. 1998. A review of the neurobehavioral deficits in children with fetal alcohol syndrome or prenatal exposure to alcohol. Alcohol Clin Exp Res 22:279-294.
104. May PA, Brooke L, Gossage JP, et al. 2000. Epidemiology of fetal alcohol syndrome in a South African community in the Western Cape Province. Am J Public Health 90:1905-1912.
105. May PA, Gossage JP, Marais AS, et al. 2007. The epidemiology of fetal alcohol syndrome and partial FAS in a South African community. Drug Alcohol Depend 88:259-271.
106. Meissner HC, Reef SE, Cochi S. 2006. Elimination of rubella from the United States: a milestone on the road to global elimination. Pediatrics 117:933-935.
107. Mensah GA, Goodman RA, Zaza S, et al. 2004. Law as a tool for preventing chronic diseases: expanding the spectrum of effective public health strategies. Prev Chronic Dis 1:A11.
108. Michaels MG, Greenberg DP, Sabo DL, et al. 2003. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 22:504-509.
109. Mills JL, Rhoads GG, Simpson JL, et al. 1989. The absence of a relation between the periconceptional use of vitamins and neural-tube defects. National Institute of Child Health and Human Development Neural Tube Defects Study Group. N Engl J Med 321:430-435.
110. Mills JL, Signore C. 2004. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol 70:844-845.
111. Milunsky A, Jick H, Jick SS, et al. 1989. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 262:2847-2852.
112. Mitchell LE. 2005. Epidemiology of neural tube defects. Am J Med Genet C Semin Med Genet 135C:88-94.
113. Mocarski ES, Jr. Shenk T, Pass RF. 2007. Cytomegaloviruses. In: Knipe DM, Howley PM, editors. Fields virology, 5th edition. Philadelphia: Lippincott Williams & Wilkins.
114. MRC Vitamin Study Research Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 338:131-137.
115. Mulinare J, Cordero JF, Erickson JD, et al. 1988. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 260:3141-3145.
116. Mulvihill JJ, Klimas JT, Stokes DC, et al. 1976. Fetal alcohol syndrome: seven new cases. Am J Obstet Gynecol 125:937-941.
117. Nelson K, Holmes LB. 1989. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 320:19-23.
118. Nelson MM, Asling CW, Evans HM. 1952. Production of multiple congenital abnormalities in young by maternal pteroylglutamic acid deficiency during gestation. J Nutr 48:61-79.
119. Nigro G, Adler SP, La Torre R, et al. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362.
120. O'Connor MJ, Whaley SE. 2007. Brief intervention for alcohol use by pregnant women. Am J Public Health 97:252-258.
121. Orenstein WA, Hinman AR. 1999. The immunization system in the United States - the role of school immunization laws. Vaccine 17:S19-24.
122. Ornoy A, Diav-Citrin O. 2006. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol 21:399-409.
123. Parkman PD, Buescher EL, Artenstein MS. 1962. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med 111:225-230.
124. Peterson J, Kirchner HL, Xue W, et al. 2008. Fatty acid ethyl esters in meconium are associated with poorer neurodevelopmental outcomes to two years of age. J Pediatr 152:788-792.
125. Pfeiffer CM, Johnson CL, Jain RB, et al. 2007. Trends in blood folate and vitamin B-12 concentrations in the United States, 1988-2004. Am J Clin Nutr 86:718-727.
126. Pfeiffer CM, Osterloh JD, Kennedy-Stephenson J, et al. 2008. Trends in circulating concentrations of total homocysteine among US adolescents and adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys. Clin Chem 54:801-13.
127. Pitt DB. 1957. Congenital malformations and maternal rubella. Med J Aust 44:233-239.
128. Plotkin SA. 2006. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis 43:S164-168.
129. Prochaska JO, Velicer WF. 1997. The transtheoretical model of health behavior change. Am J Health Promot 12:38-48.
130. Reef SE, Cochi SL. 2006. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 43:S123-125.
131. Reef SE, Redd SB, Abernathy E, et al. 1998-2004: the evidence for absence of endemic transmission. Clin Infect Dis 2006. The epidemiological profile of rubella and congenital rubella syndrome in the United States, 43:S126-132.
132. Riley HD, Jr. 1997. History of the cytomegalovirus. South Med J 90:184-190.
133. Robinson GC, Conry JL, Conry RF. 1987. Clinical profile and prevalence of fetal alcohol syndrome in an isolated community in British Columbia. CMAJ 137:203-207.
134. Robinson JL, Lee BE, Preiksaitis JK, et al. 2006. Prevention of congenital rubella syndrome-what makes sense in 2006. Epidemiol Rev 28:81-87.
135. Roebuck TM, Mattson SN, Riley EP. 1998. A review of the neuroanatomical findings in children with fetal alcohol syndrome or prenatal exposure to alcohol. Alcohol Clin Exp Res 22:339-344.
136. Ross DS, Dollard SC, Victor M, et al. 2006. The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J Womens Health (Larchmt) 15:224-229.
137. Ross DS, Victor M, Sumartojo E, et al. 2008. Women's knowledge of congenital cytomegalovirus: Results from the 2005 HealthStyles survey. J Womens Health (Larchmt) 17:849-858.
138. Roush SW, Murphy TV. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:2155-2163.
139. Rowe WP, Hartley JW, Waterman S, et al. 1956. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc Soc Exp Biol Med 92:418-424.
140. Sampson PD, Streissguth AP, Bookstein FL, et al. 1997. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology 56:317-326.
141. Schleiss MR. 2007. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J Pediatr 151:564-570.
142. Schleiss MR, Heineman TC. 2005. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4:381-406.
143. Sharpe TT, Alexander M, Hutcherson J, et al. 2004. Report from the CDC. Physician and allied health professionals? training and fetal alcohol syndrome. J Womens Health (Larchmt) 13:133-139.
144. Shepard TH, Barr M, Jr, Brent RL, et al. 2000. A history of the Teratology Society. Teratology 62:301-316.
145. Shumaker SA, Schron EB, Ockene JK, et al. 1998. The handbook of health behavior change. New York: Springer.
146. Smith MG. 1956. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 92:424-430.
147. Smithells RW, Sheppard S, Schorah CJ. 1976. Vitamin deficiencies and neural tube defects. Arch Dis Child 51:944-950.
148. Smithells RW, Sheppard S, Schorah CJ, et al. 1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1:339-340.
149. Smithells RW, Sheppard S, Schorah CJ, et al. 1981. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child 56:911-918.
150. Sokol RJ, Delaney-Black V, Nordstrom B. 2003. Fetal alcohol spectrum disorder. JAMA 290:2996-2999.
151. Stoler JM, Holmes LB. 1999. Under-recognition of prenatal alcohol effects in infants of known alcohol abusing women. J Pediatr 135:430-436.
152. Stoler JM, Holmes LB. 2004. Recognition of facial features of fetal alcohol syndrome in the newborn. Am J Med Genet C Semin Med Genet 127:21-27.
153. Stoler JM, Huntington KS, Peterson CM, et al. 1998. The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediatr 133:346-352.
154. Streissguth AP, Bookstein FL, Barr HM, et al. 2004. Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J Dev Behav Pediatr 25:228-238.
155. Streissguth AP, Dehaene P. 1993. Fetal alcohol syndrome in twins of alcoholic mothers: concordance of diagnosis and IQ. Am J Med Genet 47:857-861.
156. Surgeon General's Advisory on Alcohol Use in Pregnancy. 2005. Surgeon General Advisory on Alcohol Use in Pregnancy. Available at http://www.hhs.gov/ surgeongeneral/pressreleases/sg02222005.html. Accessed: June 1, 2008.
157. Waisbren SE, Hanley W, Levy HL, et al. 2000. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 283:756-762.
158. Watson JC, Hadler SC, Dykewicz CA, et al. 1998. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 47:1-57.
159. Weller TH, Neva FA. 1962. Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Biol Med 111:215-225.
160. Williams LJ, Mai CT, Edmonds LD, et al. 2002. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 66:33-39.
161. Williams LJ, Rasmussen SA, Flores A, et al. 1995-2002. Pediatrics 2005. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 116:580-586.
162. Witte JJ, Karchmer AW, Case G, et al. 1969. Epidemiology of rubella. Am J Dis Child 118:107-111.
163. World Health Organization. 2005. Progress towards elimination of measles and prevention of congenital rubella infection in the WHO European Region, 1990-2004. Wkly Epidemiol Rec 80:66-71.
164. Yow MD, Demmler GJ. 1992. Congenital cytomegalovirus disease-20 years is long enough. N Engl J Med 326:702-703.